Literature DB >> 29774303

Myotonia permanens with Nav1.4-G1306E displays varied phenotypes during course of life.

Frank Lehmann-Horn1, Adele D'Amico2, Enrico Bertini2, Mauro Lomonaco3, Luciano Merlini4, Kevin R Nelson5, Heike Philippi6, Gabriele Siciliano7, Frank Spaans8, Karin Jurkat-Rott9.   

Abstract

INTRODUCTION: Myotonia permanens due to Nav1.4-G1306E is a rare sodium channelopathy with potentially life-threatening respiratory complications. Our goal was to study phenotypic variability throughout life.
METHODS: Clinical neurophysiology and genetic analysis were performed. Using existing functional expression data we determined the sodium window by integration.
RESULTS: In 10 unrelated patients who were believed to have epilepsy, respiratory disease or Schwartz-Jampel syndrome, we made the same prima facie diagnosis and detected the same heterologous Nav1.4-G1306E channel mutation as for our first myotonia permanens patient published in 1993. Eight mutations were de-novo, two were inherited from the affected parent each. Seven patients improved with age, one had a benign phenotype from birth, and two died of respiratory complications. The clinical features age-dependently varied with severe neonatal episodic laryngospasm in childhood and myotonia throughout life. Weakness of varying degrees was present. The responses to cold, exercise and warm-up were different for lower than for upper extremities. Spontaneous membrane depolarization increased frequency and decreased size of action potentials; self-generated repolarization did the opposite. The overlapping of steady-state activation and inactivation curves generated a 3.1-fold window area for G1306E vs. normal channels. DISCUSSION: Residue G1306 Neonatal laryngospasm and unusual distribution of myotonia, muscle hypertrophy, and weakness encourage direct search for the G1306E mutation, a hotspot for de-novo mutations. Successful therapy with the sodium channel blocker flecainide is due to stabilization of the inactivated state and special effectiveness for enlarged window currents. Our G1306E collection is the first genetically clarified case series from newborn period to adulthood and therefore helpful for counselling.

Entities:  

Keywords:  muscular and respiratory tract diseases; neonate; stridor

Mesh:

Substances:

Year:  2017        PMID: 29774303      PMCID: PMC5953224     

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  20 in total

1.  K-aggravated myotonia mutations at residue G1306 differentially alter deactivation gating of human skeletal muscle sodium channels.

Authors:  James R Groome; Esther Fujimoto; Peter C Ruben
Journal:  Cell Mol Neurobiol       Date:  2005-11       Impact factor: 5.046

2.  Neonatal hypotonia can be a sodium channelopathy: recognition of a new phenotype.

Authors:  E Matthews; A Guet; M Mayer; S Vicart; S Pemble; D Sternberg; B Fontaine; M G Hanna
Journal:  Neurology       Date:  2008-11-18       Impact factor: 9.910

3.  Schwartz-Jampel syndrome: II. Na+ channel defect causes myotonia.

Authors:  F Lehmann-Horn; P A Iaizzo; C Franke; H Hatt; F Spaans
Journal:  Muscle Nerve       Date:  1990-06       Impact factor: 3.217

4.  Different effects on gating of three myotonia-causing mutations in the inactivation gate of the human muscle sodium channel.

Authors:  N Mitrović; A L George; H Lerche; S Wagner; C Fahlke; F Lehmann-Horn
Journal:  J Physiol       Date:  1995-08-15       Impact factor: 5.182

5.  Diagnosis and outcome of SCN4A-related severe neonatal episodic laryngospasm (SNEL): 2 new cases.

Authors:  Emilie Caietta; Mathieu Milh; Damien Sternberg; Anne Lépine; Christophe Boulay; Aileen McGonigal; Brigitte Chabrol
Journal:  Pediatrics       Date:  2013-08-19       Impact factor: 7.124

6.  Stridor as a neonatal presentation of skeletal muscle sodium channelopathy.

Authors:  Emma Matthews; Adnan Y Manzur; Richa Sud; Francesco Muntoni; Michael G Hanna
Journal:  Arch Neurol       Date:  2011-01

7.  Mechanisms underlying a life-threatening skeletal muscle Na+ channel disorder.

Authors:  Dina Simkin; Isabelle Léna; Pierre Landrieu; Laurence Lion-François; Damien Sternberg; Bertrand Fontaine; Saïd Bendahhou
Journal:  J Physiol       Date:  2011-04-26       Impact factor: 5.182

8.  Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block.

Authors:  Jean-François Desaphy; Annamaria De Luca; Maria Paola Didonna; Alfred L George; Diana Camerino Conte; Annamaria D E Luca
Journal:  J Physiol       Date:  2003-11-07       Impact factor: 5.182

Review 9.  Flecainide-Responsive Myotonia Permanens With SNEL Onset: A New Case and Literature Review.

Authors:  Simona Portaro; Carmelo Rodolico; Stefano Sinicropi; Olimpia Musumeci; Mariella Valenzise; Antonio Toscano
Journal:  Pediatrics       Date:  2016-03-04       Impact factor: 7.124

10.  Mutations in SCN4A: a rare but treatable cause of recurrent life-threatening laryngospasm.

Authors:  Rahul R Singh; S Veronica Tan; Michael G Hanna; Stephanie A Robb; Antonia Clarke; Heinz Jungbluth
Journal:  Pediatrics       Date:  2014-10-13       Impact factor: 7.124

View more
  4 in total

Review 1.  Treatment Updates for Neuromuscular Channelopathies.

Authors:  Nantaporn Jitpimolmard; Emma Matthews; Doreen Fialho
Journal:  Curr Treat Options Neurol       Date:  2020-08-22       Impact factor: 3.598

2.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

3.  Possible role of SCN4A skeletal muscle mutation in apnea during seizure.

Authors:  Dilşad Türkdoğan; Emma Matthews; Sunay Usluer; Aslı Gündoğdu; Kayıhan Uluç; Roope Mannikko; Michael G Hanna; Sanjay M Sisodiya; Hande S Çağlayan
Journal:  Epilepsia Open       Date:  2019-07-01

Review 4.  An Up-to-Date Overview of the Complexity of Genotype-Phenotype Relationships in Myotonic Channelopathies.

Authors:  Fernando Morales; Michael Pusch
Journal:  Front Neurol       Date:  2020-01-17       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.